Introduction
============

Breast cancer is one of the most genetically heterogeneous cancers. It is also one of the most commonly diagnosed cancers and the second most common cause of cancer mortality in women ([@b1-ijo-49-06-2245]). Despite the improvement of current screening methods which rely on imaging techniques and the targeted classification of breast cancer based primarily on hormone receptors (estrogen and progesterone) and the HER2/NEU status, mortality remains high for advanced breast cancer, particularly when drug resistance develops.

Since Warburg first hypothesized that cancer cells had a significantly higher rate of glycolysis than normal cells ([@b2-ijo-49-06-2245]), researchers have shown that changes in metabolism can lead to large changes in metabolites that occur downstream of genomic and proteomic alterations ([@b3-ijo-49-06-2245],[@b4-ijo-49-06-2245]). How signal pathways control energy metabolism in cancer cells has become a high priority in cancer research, reflecting an increased focus on the interaction of gene expression (i.e. receptors), microenvironment (i.e. hypoxia), and glucose metabolism, and how the downstream expression of metabolites can be used for both early detection of breast cancer as well as targeted drug therapies ([@b5-ijo-49-06-2245]--[@b7-ijo-49-06-2245]).

Traditional methods of analysis have evolved into large-scale data gathering through different 'omics' approaches: genomics, transcriptomics, proteomics and more recently, metabolomics. This latter growing technology permits simultaneous monitoring of thousands of macro and micro metabolites that serve as substrates and products of metabolic pathways ([@b8-ijo-49-06-2245]). Integration of these pathways and their interactions provides insight into the development of malignant processes and could lead to the discovery of cancer biomarkers ([@b9-ijo-49-06-2245]).

Several studies have demonstrated the efficacy of using metabolomics to discriminate between cancer and normal tissues in different organs including the breast. Sitter *et al* ([@b10-ijo-49-06-2245]) analyzed 88 tumor samples from breast cancer patients and 18 tissue samples from adjacent non-tumor tissue using high-resolution magic-angle spinning magnetic resonance spectroscopy (HRMAS). Principal component analysis (PCA) allowed for correct sample classification in the majority of the cases with 82% sensitivity and 100% specificity. Mountford *et al* ([@b11-ijo-49-06-2245]) performed proton nuclear magnetic resonance (^1^HNMR) spectroscopy analysis of breast tumor extracts. Fine needle aspiration biopsies from 140 patients with breast lumps (83 malignant and 57 benign) were analyzed by ^1^HNMR spectroscopy. Using a classification strategy, they were able to classify samples as malignant or benign with a sensitivity and specificity of 93 and 92%, respectively. More recently, using high-throughput gas chromatography with time-of-flight mass spectrometer (GC-TOFMS)-based metabolomic analysis, Budczies *et al* ([@b12-ijo-49-06-2245]) identified significant differences between metabolites from breast tumors compared to normal tissues, specifically the cytidine-5-monophosphate/pentadecanoic acid metabolic ratio. This allowed the discrimination between normal and cancer tissue samples with high specificity (93.9%) and high sensitivity (94.8%). Furthermore, a comparison of estrogen receptor positive and estrogen receptor negative breast cancer revealed significant changes in glutamine and β-alanine metabolism between these two breast cancer subtypes ([@b13-ijo-49-06-2245]). Metabolomic profiling was used to discriminate between localized early breast cancer and advanced metastatic disease ([@b14-ijo-49-06-2245]), and to develop a prediction model for the early detection of recurrent breast cancer from serum samples ([@b15-ijo-49-06-2245]). Of interest, Budhu *et al* ([@b16-ijo-49-06-2245]), showed that there was a specific metabolomic signature of tumors depending on the tissue of origin and suggested that the metabolites were generally unique for each tissue and cancer type. Comparing the metabolic changes between cancer and normal cells could identify the metabolic reprograming involved in tissue specific tumorigenesis.

To date, metabolomic analysis has been performed on many different tissue types, including solid tissues, serum, plasma and urine ([@b17-ijo-49-06-2245]). Originally, ductal lavage (DL) and nipple aspirate fluid (NAF) were used for cytological evaluation of breast epithelial cells in the ductal fluid. They have also been used for different molecular studies. However, because they contain proteins and metabolites of breast tissue metabolism in addition to ductal epithelial cells, they are very useful for metabolomic studies, thus providing a unique opportunity to evaluate more directly metabolomic changes in the breast tumor microenvironment itself and avoiding questions of tissue specificity, which arise when evaluating blood and urine. The feasibility of performing metabolomic analysis in NAF was recently demonstrated in a small study of eight subjects ([@b18-ijo-49-06-2245]). The study was conducted on samples obtained from healthy pre- and post-menopausal individuals and compared the findings in NAF with matching plasma samples from the same patients. They showed that NAF is metabolically distinct from matched plasma samples which supports the theory that the cellular environment (tumor microenvironment) is more directly mirrored in breast biofluids (DL and NAF). We have recently identified a panel of microRNAs that are differentially expressed in ductal fluid from breasts with tumors compared to paired ductal fluid samples from the contralateral normal breast ([@b19-ijo-49-06-2245]), further substantiating the importance of a more direct analysis of the tumor microenvironment and the potential for biomarker development using ductal fluid obtained in a non-invasive or minimally invasive approach. Here, we report the first metabolomic analysis of breast ductal fluid samples obtained from 43 patients with unilateral breast cancer. We evaluated paired samples from the breast with cancer compared to the contralateral non-affected breast (control) and identified several metabolites with significant changes in levels between affected and non-affected breasts. This approach provides an exciting opportunity to detect metabolomic changes in the cellular microenvironment reflecting tumor evolution, and has the potential for significantly improving breast cancer screening and detection

Materials and methods
=====================

Patient population
------------------

We enrolled 43 patients with unilateral, biopsy-confirmed, breast tumors \[invasive breast cancer (IBC) and/or ductal carcinoma *in situ* (DCIS)\], who were scheduled for surgery (mastectomy/lumpectomy) at the MedStar Georgetown University Hospital. Patients were identified by the surgeon and offered the opportunity to participate in the study. If they agreed, they were asked to sign an IRB-approved informed consent.

Ductal lavage
-------------

Prior to starting the operative procedure, for each subject, the surgeon obtained breast ductal fluid from the affected breast and the non-affected contralateral breast, using ductal lavage. Each patient served as her own control. The ductal lavage procedure was performed as previously described ([@b20-ijo-49-06-2245]), except that the collected fluid was placed in a sterile tube with no preservative solution, and was transferred immediately to the laboratory, and divided into different aliquots which were frozen at −80°C for future studies. One fresh aliquot was used for cytopathology evaluation to investigate the presence of benign, atypical or malignant cells by a certified breast pathologist, using the established criteria for ductal lavage cytologic analysis ([@b21-ijo-49-06-2245]).

Metabolite extraction from ductal lavage
----------------------------------------

Metabolite extraction was performed as per the protocol described by Sheikh *et al* ([@b22-ijo-49-06-2245]). Briefly, 150 μl of ductal lavage fluid was plunged into dry ice for 30 sec followed by heat shock at 37°C for 30 sec. A total of 600 μl of methanol containing 4-nitrobenzoic acid and debrisoquine were then added and the samples were vortexed, transferred to room temperature and extracted with chloroform. The tubes were transferred to −20°C for overnight incubation and subsequently centrifuged at 4°C for 10 min at 12,000 rpm. The top and bottom phases were transferred to different tubes carefully avoiding the middle interface (containing precipitated proteins). An equivalent amount of chilled acetonitrile (ACN) was then added and the samples cooled on ice for 15 min after vortexing. Samples were centrifuged at 4°C for 10 min at 12,000 rpm and the supernatant was transferred to a fresh tube and dried under vacuum. The residual pellet was re-suspended in 200 μl of solvent A (98% water, 2% ACN and 0.1% formic acid) for UPLC-Q-TOF/MS analysis.

UPLC-QTOF data acquisition
--------------------------

Each sample (5 μl) was injected onto a reverse-phase 50 × 2.1 mm BEH 1.7 μm C18 column using an Acquity UPLC system (Waters Corp., Milford, MA, USA). The mobile phase comprised of water containing 0.1% formic acid solution (A) and acetonitrile containing 0.1% formic acid solution (B). Each sample was resolved for 10 min at a flow rate of 0.5 ml/min. This approach has been extensively used for metabolomic profiling of biofluids; UPLC gradient conditions and the mass spectrometry parameters have been described in detail ([@b23-ijo-49-06-2245],[@b24-ijo-49-06-2245]). The column eluent was introduced directly into the mass spectrometer by electrospray. Mass spectrometry was performed on a Quadrupole-time-of-flight mass spectrometer operating in either negative or positive electrospray ionization mode with a capillary voltage of 3.2 kV and a sampling cone voltage of 35 V. The desolvation gas flow was 800 l/h and the temperature was set to 350°C. The cone gas flow was 50 l/h, and the source temperature was 150°C. Accurate mass was maintained by infusing sulfadimethoxine (311.0814 m/z) in 50% aqueous acetonitrile (250 pg/μl) at a rate of 30 μl/min via the lockspray interface every 10 sec. Data were acquired in centroid mode from 50 to 850 m/z mass range for TOF-MS scanning, in duplicate (technical replicates) for each sample in positive and negative ionization mode and checked for chromatographic reproducibility. For all profiling experiments, the sample queue was staggered by randomizing samples to eliminate bias. We acquired UPLC-QTOF data by analysis of DL from 43 subjects. For each subject two samples, one from the affected and one from the contralateral normal breast, were generated. Each sample was injected twice.

Data preprocessing
------------------

The raw UPLC-QTOF data were converted into Network Common Data Format (NetCDF) using the MassLynx software (Waters Corp.). The R-package XCMS (Scripps Center for Metabolomics, La Jolla, CA, USA) was used to preprocess the datasets acquired in the electro-spray positive and negative ion modes. The first step in XCMS is to detect the peaks. The peak detection algorithm first cuts the data into slices, a fraction of a mass unit wide, and then applies a model peak matched filter on those individual slices over the chromatographic time domain. After detecting peaks in individual samples, the peaks are matched across samples to allow calculation of retention time (RT) deviations and relative ion intensity comparison. This is accomplished using a grouping method that uses kernel density estimation to group peaks in the mass domain. The peak matching algorithm in XCMS takes into account the two-dimensional anisotropic nature of data. These groups are then used to identify and correct drifts in RT from run to run.

Following peak matching, we used the R-package CAMERA to identify derivative ions originating from the same compound in the form of adducts, isotopes, and in-source fragments ([@b25-ijo-49-06-2245]). Adducts of a molecule are formed during the electrospray ionization (ESI) process, e.g. sodium and ammonium adduct. Ions of molecular isotopes are detected with distinct m/z values during MS analysis and the peak with the lowest m/z is defined as the monoisotopic peak. In-source fragments are formed during ionization such as ion fragments of \[M+H-H~2~O\]^+^ or \[M-H-H~2~O\]^−^ through neutral loss of water molecule. Different adducts/isotopes/water-loss products of the same compound theoretically share the same retention time in chromatograms. As long as the scan rate is properly adjusted and enough scanning points are acquired to define the chromatographic peaks, the ions from the same compound share similar-shaped elution profiles which can be represented by their extracted ion chromatograms (EICs). Thus, clustering of similar elution profiles was performed by CAMERA prior to statistical analysis. Recognition of such metabolites, often represented by multiple peaks with distinct m/z values at similar retention times, can facilitate metabolite identification in LC-MS based metabolomics.

Statistical analysis
--------------------

To identify ions with significant changes in intensity levels, we used parametric statistical methods that we implemented in-house using MATLAB (MathWorks, Natick, MA, USA) and R scripts. Before performing the statistical analysis, intensities from double injections were averaged to achieve a single intensity for each right or left DL sample. For pre-screening of ions, both univariate analyses and multivariate analyses were performed. For each ion, paired t-tests were performed to compare profiles of metabolites between the tumor samples and the paired normal samples. P-values obtained from multiple testing were adjusted to q-values based on Storey\'s method ([@b26-ijo-49-06-2245]). A robust pairwise fold change (FC) was calculated based on the median of the relative intensity of tumor/normal samples for each pair. In addition, we performed principal component analysis (PCA) and multilevel PLS-DA (MPLS-DA) that accounts for the paired data ([@b27-ijo-49-06-2245]). The first screening was performed based on q-values \<0.05. To further identify which ions are associated with the normal/tumor tissues, generalized LASSO regression adjusting for race, menopausal status, smoking, grade, and TNM stage and conditional logistic regression with LASSO penalties were fitted where LASSO penalty parameters were determined through 10-fold cross-validation (using the 'glmnet' and 'clogitL1' R package, respectively) ([@b28-ijo-49-06-2245],[@b29-ijo-49-06-2245]). Conditional logistic regression with the selected ions was employed as a predictive model where the diagnostic performance of the selected ions was assessed using the area under the receiver operating characteristic (ROC) curves. In addition, one way ANOVA and linear regression were used to compare cancer metabolomic profiles of LASSO selected ions across different demographic and clinical characteristics.

Putative identifications for the resulting ion list were obtained through a mass-based search using MetaboSearch ([@b30-ijo-49-06-2245]), which searches for putative identifications against four databases: the Human Metabolite DataBase (HMDB) ([@b31-ijo-49-06-2245]), Metlin ([@b32-ijo-49-06-2245]), Madison Metabolomics Consortium Database (MMCD) ([@b33-ijo-49-06-2245]), and LIPID MAPS ([@b34-ijo-49-06-2245]). The mass tolerance in the database search was set to 10 ppm. The m/z values of annotated isotopes/adducts/in-source fragments peaks were converted to the corresponding neutral mono-isotopic masses before searching them against the databases. Identities of a subset of the putative metabolite identifications were verified by comparing their MS/MS fragmentation patterns and RT with those of authentic standard compounds.

Results
=======

Clinical and tumor characteristics of the patients are summarized in [Table I](#tI-ijo-49-06-2245){ref-type="table"}. Our patient population was 52 years of age on average, the majority being post-menopausal (58%). Approximately 60% of our patients were white, and a quarter of them were African Americans. The great majority were never or former smokers. Most of the tumors were invasive ductal carcinoma (IDC) (72%), early stage (I and II) (81%), with no lymph node involvement (67%), hormone receptor positive (88% ER^+^, 70% PR^+^), and HER2 negative (70%). More than two thirds of our patients had insufficient cells for analysis in the ductal lavage samples from the affected breast (70%), emphasizing the limitation of ductal lavage cytology for detecting breast cancer. Subjects who received pre-operative chemotherapy were excluded from the study.

Preprocessing of the UPLC-QTOF data identified 2098 ions, 1560 ions in the positive mode and 538 ions in negative mode ([Table II](#tII-ijo-49-06-2245){ref-type="table"}). These data matrices were used to select ions with significant differences between ductal lavage fluid from the affected breast and the non-affected contralateral control breast. Paired t-tests were applied on these data matrices and identified 209 ions, out of the 2,098 ions, with q-values \<0.05 ([Table II](#tII-ijo-49-06-2245){ref-type="table"}). Among the 209 significant ions, 66 (31.6%) were assigned putative compound names by MetaboSearch. When ranking these ions according to the fold change (FC) in ion intensity levels between the affected and non-affected breasts, 83 (39.7%) metabolites showed an FC ≥1.2, 37 of these, being metabolites with a putative compound name identified through the databases. The great majority of these compounds were most likely of exogenous origin, being found in plants, dietary supplements or drugs; however, some were endogenous metabolites such as amino acid derivatives (N-Acetyl-DL-tryptophan, FC=−2.02, P=0.006) or products of lipid metabolism such as N-linoleoyl taurine (FC=−1.24, P=0.001), trans-2-dodecenoylcarnitine (FC=−3.58, P=0.006), lysophosphatidylcholine LysoPC(18:2(9Z,12Z)) (FC=−1.20, P=0.018), and glycerophospholipids PG(18:0/0:0) (FC=−1.45, P=0.018) and phosphatidylserine PS(20:4(5Z,8Z,11Z,14Z) (FC=−1.49, P\<0.001). Logistic regression with LASSO penalties further selected 21 metabolites, when race, menopausal status, smoking, grade and TNM stage were adjusted for ([Table III](#tIII-ijo-49-06-2245){ref-type="table"}). However, conditional logistic regression with LASSO penalties yielded five ions where the predictive model does not provide adequate prediction performance (AUC=0.679, sensitivity/specificity of 0.744/0.581). Thus, further inferences focused on the 21 ions.

We performed principal component analysis (PCA) and multilevel PLS-DA (MPLS-DA) that accounts for the cross-over data and examined the performance of selected biomarkers. The PCA plot based on the 21 ions (identified using the LASSO regression analysis; [Fig. 1B](#f1-ijo-49-06-2245){ref-type="fig"}) shows visually better clustering performances of both sets of ions than the PCA plot based on 209 ions (q-values \<0.05; [Fig. 1A](#f1-ijo-49-06-2245){ref-type="fig"}).

We evaluated whether the LASSO-selected 21 ions can be used as potential biomarkers for breast cancer detection. Conditional logistic regression with the 21 ions was employed as a predictive model where the diagnostic performance of the 21 ions was assessed using the area under the receiver operating characteristic (ROC) curves. ROC based on the conditional logistic regression model gave highly accurate diagnostic performance with an area under the curve (AUC) of 0.956 along with a sensitivity of 90.7% and specificity of 88.4% ([Fig. 2](#f2-ijo-49-06-2245){ref-type="fig"}). In addition, one way ANOVA and linear regression were used to compare cancer metabolomic profiles of the LASSO-selected ions across different demographic and clinical characteristics. Among the 21 LASSO-identified ions, we found ten metabolites that show statistically significant differences based on menopausal status (pre/post), ER (+/−), and HER2 (+/−). [Table IV](#tIV-ijo-49-06-2245){ref-type="table"} shows these metabolites. P-values are in bold for the metabolites with P\<0.05.

We found that menopausal status can affect the level of metabolite expression among our patients. Three metabolites (M179.1841, M121.2079 and M466.729) are higher in post-menopausal patients (P\<0.05; [Table IV](#tIV-ijo-49-06-2245){ref-type="table"}). On the other hand, one metabolite (M622.627) is higher in pre-menopausal patients (P=0.040; [Table IV](#tIV-ijo-49-06-2245){ref-type="table"}). HER2 positive receptor status also shows an association with increased levels of metabolites (M724.491 and M788.4464) in patients (P\<0.005; [Table IV](#tIV-ijo-49-06-2245){ref-type="table"}), while four metabolites (M121.2079, M178.0316, M417.1127 and M454.4747) are lower in HER2 positive patients (P\<0.05; [Table IV](#tIV-ijo-49-06-2245){ref-type="table"}).

From the list of 209 significant monoisotopic ions with putative identifications, we selected eight metabolites with putative IDs and standard compounds for verification by comparing their TOF-MS/MS spectra against their corresponding synthetic compounds. Specifically, we ran an authentic compound for each candidate and a patient sample side by side and compared the fragmentation patterns and their LC retention time. We were able to verify six metabolites against their standards, experimentally. [Table V](#tV-ijo-49-06-2245){ref-type="table"} shows a list of the six verified and two unverified metabolites, and [Fig. 3](#f3-ijo-49-06-2245){ref-type="fig"} shows an example of the verification result for N-acetyl-DL-tryptophan, comparing the fragmentation pattern of the analyte in ductal lavage against the pattern obtained from an authentic compound.

Discussion
==========

The emerging technology of metabolomics has provided insights into cancer metabolic pathways in different organs, including the mammary gland, which can lead to the discovery of new cancer biomarkers and therapies. To the best of our knowledge, this is the first study that compares the metabolomic profiles in the ductal fluid from cancer affected breasts vs. non-affected contralateral control breasts in the same subjects, allowing us to view the metabolites in the tumor microenvironment where breast cancer arises, in a unique well-controlled setting where each patient serves as her own control.

We analyzed ductal fluid samples obtained by ductal lavage from 43 subjects with unilateral breast cancer from both the affected breast and the contralateral non-affected control breast and identified 209 ions that showed a significant difference in intensity levels (q-values \<0.05) between the fluid from the affected breast vs. the fluid from the non-affected control breast. We observed significant differences between the fluid from the affected breast vs. the fluid from the non-affected control breast in the levels of tryptophan, products of lipid metabolism, derivatives of amino acid metabolism and phospholipids.

Interestingly, metabolomic profiles are not only different between cancer and normal tissue as we and others have shown, but also are cancer tissue type specific ([@b16-ijo-49-06-2245],[@b35-ijo-49-06-2245]). In addition, specific metabolite changes occur at earlier stages for each tissue and cancer type. For instance, amino acid related metabolites, such as N-Acetyl-amino acids, and lipid related metabolites, such as carnitine and glycerophopsholipids, were shown to be significantly altered in breast tumors ([@b14-ijo-49-06-2245],[@b16-ijo-49-06-2245]); in serum, amino acid changes were mainly observed in early stage breast cancer (stages I and II) compared to metastatic disease ([@b14-ijo-49-06-2245]). A supervised class comparison analysis of tumor vs. non-tumor tissues revealed specific metabolites that could discriminate between liver, pancreas and breast, with the most evident differences occurring in amino acid and lipid pathways; glycerol and linolenate were upregulated only in breast tumors ([@b16-ijo-49-06-2245]). In individuals with early stage disease, 8 metabolites were significantly and uniquely altered in breast tumors vs. normal tissues; in a similar analysis, 81 metabolites in liver and 18 in pancreatic tumors were significantly and differentially altered ([@b16-ijo-49-06-2245]). Comparing the metabolic changes between tissue specific cancer and normal cells could pinpoint the metabolic reprograming involved in tissue specific tumorigenesis.

In the present study we identified lower levels of N-Acetyl-DL-tryptophan in the fluid from the affected breasts compared to the control breast fluid, consistent with previous reports showing decreased amino acid metabolites in breast cancer ([@b36-ijo-49-06-2245]--[@b38-ijo-49-06-2245]). Cancer metabolism requires energy derived from both anaerobic and aerobic glycolysis, which means lower substrate levels like glucose and glutamine being siphoned off to the tricarboxylic acid (TCA) cycle, and higher levels of bioenergic substrates, like lactate, which stimulates continuous growth ([@b36-ijo-49-06-2245]). In a recent study, Willmann *et al* ([@b39-ijo-49-06-2245]), used metabolomic profiling to sub-classify different breast cancer cell lines and differentiate not only between them, but also between the cancer cell lines and a non-cancer breast epithelial cell line as well. Research has shown that elevated glycine and lactate indicate increased metabolic changes due to rapid growth of cancer cells, and hence poorer prognosis ([@b5-ijo-49-06-2245]).

Levels of metabolites were also reported to differ by race ([@b38-ijo-49-06-2245]). However, in this study, we were not able to detect a statistically significant difference in the metabolite levels based on the subjects\' race possibly due to the small sample size per each race. None of the LASSO-identified 21 ions showed statistically significant difference among patients based on race (minimum P-values \>0.50; data not shown).

When we stratified our patients by receptor status, we observed that the M239.1486 metabolite tends to be less expressed in ER^+^ patients (P=0.045; [Table IV](#tIV-ijo-49-06-2245){ref-type="table"}). Fan *et al* ([@b35-ijo-49-06-2245]) analyzed plasma metabolite profiles of 96 breast cancer patients compared to 79 normal controls by UPLC-Q/TOF-MS and GC-Q/MS, and identified several metabolites that could discriminate between breast cancer and controls, and also between breast cancer subtypes according to HER2 and estrogen receptor status. ER positive (ER^+^) patients showed elevated alanine, aspartate and glutamate metabolism, decreased glycerolipid catabolism and enhanced purine metabolism compared to the ER negative (ER^−^) group (also described in plasma metabolites from breast cancer patients vs. normal controls ([@b38-ijo-49-06-2245]). ER^−^ and triple-negative receptor status is indicative of more aggressive tumors and a poorer prognosis. In breast cancer, the substrate glutamine and end product lactate enhance cancer aggressiveness; additionally ER^−^ breast cancers are dependent upon serine synthesis for continued growth ([@b36-ijo-49-06-2245]).

In the present study, metabolites involved in lipid signaling were decreased in the fluid from the breasts with tumors, similar to previously published study ([@b36-ijo-49-06-2245]). Lower levels of lysophosphatidylcholines and higher levels of sphingomyelins and acylcarnitines were detected in the plasma of cancer patients compared to controls ([@b37-ijo-49-06-2245]). The decrease in glycerophopsholipid levels in cancer patients may be due to a higher expression of phospholipase A2 (PLA2), a gene encoding for the enzymes responsible for their metabolism ([@b37-ijo-49-06-2245]), and whose expression was found to be upregulated in breast cancer cell lines and tissues ([@b40-ijo-49-06-2245],[@b41-ijo-49-06-2245]). Higher levels of lipid metabolites, including fatty acids and carnitine metabolites, have been found in breast cancer patients compared to normal controls ([@b35-ijo-49-06-2245],[@b38-ijo-49-06-2245],[@b42-ijo-49-06-2245]). Wang *et al* ([@b9-ijo-49-06-2245]) reported that several lipids including phosphatidylglycerol (PG) were upregulated in highly invasive breast cancer cells. Breast tumors are described as developing a 'lipogenic phenotype', and while cell growth is dependent on lipogenesis, lipolysis is upregulated, and is associated with tumor aggressiveness ([@b36-ijo-49-06-2245],[@b37-ijo-49-06-2245]).

Although our findings do not show exactly the same metabolites being altered as reported in other studies, the metabolites that we identified belong to the same class of compounds and same metabolic pathways, especially in the case of lipid metabolites. Cancer cells have been shown to have an increased glucose uptake (Warburg effect), conversion to lactate (glycolysis) and changes in protein and lipid metabolism ([@b43-ijo-49-06-2245]). Some differences between studies can be attributed to the biological specimens analyzed (ductal lavage) vs. tissue and blood, or to technical or methodological differences. Moreover, a large part of the differentially expressed metabolites from the present study are still unknown, emphasizing the complexity of metabolic alterations in cancer.

Because the ductal lavage samples were collected under anesthesia immediately before surgery when the patient was already medicated, we identified many drug-related metabolites in our samples. However, because many of these drug-related metabolites were different between the breasts with tumors and normal breasts, this altered drug metabolism in the affected breast could be of possible therapeutic benefit and requires additional analysis. Identification of the specific metabolites could be used to target specific enzymes. Enzyme expression levels and metabolic pathways could be used to target specific breast cancer phenotypes, or cancer cell survival within tumors ([@b7-ijo-49-06-2245]).

A metabolomics based profile for the early detection of breast cancer recurrence has been developed by Asiago *et al* ([@b15-ijo-49-06-2245]). They used 11 metabolites in their prediction model, several of which we have reported as being significantly differentially expressed in the ductal lavage samples. A follow-up analysis of our patients might yield comparable results and contribute to improving earlier detection and better treatment in the cases of breast cancer recurrence.

Although our study design was unique in that we used ductal fluid obtained from the contralateral normal breast for comparison, which allowed us to control for several variables that could not have been controlled for otherwise, a drawback of such a design is the possibility that the contra-lateral breast cells may already harbor metabolomic changes. We, and others, have shown that genomic aberrations occur very early in tumorigenesis and may precede morphologic changes (20,44--46). Therefore, we cannot rule out the possibility of similar changes affecting some metabolites in the contralateral clinically normal breast. A future study may include an additional control group of normal subjects (e.g., patients undergoing reduction mammoplasty) to account for this possibility.

In summary, this is the first study to assess metabolomic profiles in ductal fluid samples from breast cancer patients. The differences we saw were directly related to the tumor microenvironment and provide a snapshot of ongoing breast cancer metabolism. However, the identification of several metabolites with altered levels in the cancer affected breast, especially lipid related metabolites, previously reported in breast cancer tissue, cell lines and the circulation, provide confidence that these could constitute the basis for metabolomics based markers for breast cancer detection. This study shows the feasibility of conducting a comprehensive metabolomic profiling of breast tumors using breast ductal fluid to detect changes in the cellular microenvironment of the tumors and shows the potential for this approach to be used to improve detection of breast cancer.
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![MPLS-DA score plot shows the separation between two class labels (normal and tumor) based on (A) the significant 209 ions with q-value \<0.05 and (B) the 21 ions that were selected from LASSO regression with the pre-screened 209 ions.](IJO-49-06-2245-g00){#f1-ijo-49-06-2245}

![Receiver operating characteristics (ROC) curve with the area under curve (AUC) showing the prediction performance of the 21 selected ions with a sensitivity and specificity of 90.7 and 88.4%, respectively, when the cut-off was set to 0.27.](IJO-49-06-2245-g01){#f2-ijo-49-06-2245}

![Verification of putative ID with mass 247.1071. Top panel is the MS/MS spectrum of the ion obtained in the ductal lavage samples and bottom panel is the MS/MS spectrum of authentic compound N-Acetyl-DL-tryptophan.](IJO-49-06-2245-g02){#f3-ijo-49-06-2245}

###### 

Subject characteristics.

  Characteristics                   N                \%[a](#tfn1-ijo-49-06-2245){ref-type="table-fn"}
  --------------------------------- ---------------- --------------------------------------------------
  Age (mean ± SD)                   52.20 (±12.25)   
  Menopause                                          
   Pre                              18               41.86
   Post                             25               58.14
  Race/Ethnicity                                     
   A                                4                9.30
   AA                               11               25.59
   CA                               26               60.46
   H                                2                4.65
  Family history of breast cancer                    
   Yes                              18               41.86
   No                               25               58.14
  Tumor site                                         
   Right                            16               37.21
   Left                             27               62.79
  Smoking history                                    
   Current                          4                9.30
   Former                           7                16.28
   Never                            32               74.42
  Histological type                                  
   DCIS                             7                16.28
   IDC                              31               72.10
   ILC                              4                9.30
   Mixed                            1                2.32
  Stage                                              
   0                                7                16.28
   I                                17               39.54
   II                               18               41.86
   III                              1                2.32
  Grade                                              
   Low                              3                6.98
   Intermediate                     14               32.56
   High                             26               60.46
  Lymph node involvement                             
   Yes                              13               30.23
   No                               29               67.44
  ER                                                 
   Positive                         38               88.37
   Negative                         5                11.63
  PR                                                 
   Positive                         30               69.77
   Negative                         13               30.23
  HER2                                               
   Positive                         8                18.60
   Negative                         30               69.77
  Affected breast cytology                           
   Atypical cells                   4                9.30
   Benign cells                     9                20.93
   Insufficient cells               30               69.77

May not add to 100% due to missing values.

A, Asian; AA, African American; CA, Caucasian; H, Hispanic; DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

###### 

Number of ions detected and those selected by statistical analysis.

  Mode       No. of ions detected   No. of ions with adjusted P-value \<0.05   No. of ions selected by LASSO
  ---------- ---------------------- ------------------------------------------ -------------------------------
  Positive   1560                   197                                        19
  Negative   538                    12                                         2

###### 

Metabolites selected by LASSO.

  Metabolite ID                              Formula       Exact mass    ID (KEGG/HMDB)   Mode   m/z           RT      Cases vs. control   Fold change   Adjusted P-value
  ------------------------------------------ ------------- ------------- ---------------- ------ ------------- ------- ------------------- ------------- ------------------
  Putative identification                                                                                                                                
  3,6,9,12,15,18-Hexaoxaicosaine-1,20-diol   C14H30O8      326.1940679                    \+     327.2019744   128.9   ↓                   −1.29         0.0289
  Angustifoline                              C14H22N2O     234.1732133   C10751           \+     235.1805058   143.4   ↑                   5.11          0.0289
  Pentaethylene glycol                       C10H22O6      238.1416384                    \+     239.1485614   109.0   ↓                   −3.58         0.0289
  Peroxyacetic acid uroporphyrin III         C39H36N4O17   832.2075458   HMDB03330        \+     417.1126579   338.3   ↓                   −1.17         0.0289
  No identification                                                                                                                                      
                                                                                          \+     178.0315745   136.0   ↓                   −1.32         0.0013
                                                                                          \+     788.4464449   20.4    ↓                   −1.23         0.0021
                                                                                          \+     414.8635376   17.2    ↓                   −1.10         0.0046
                                                                                          \+     417.8067865   338.1   ↑                   1.04          0.0046
                                                                                          \+     179.1841366   135.9   ↓                   −1.66         0.0110
                                                                                          \+     454.8053723   338.2   ↑                   1.06          0.0110
                                                                                          −      466.7290136   17.9    ↑                   1.05          0.0171
                                                                                          \+     121.2079108   338.4   ↑                   1.12          0.0196
                                                                                          \+     808.5359146   18.4    ↓                   −1.04         0.0196
                                                                                          \+     454.4746506   337.7   ↑                   1.05          0.0289
                                                                                          \+     636.3472375   174.4   ↑                   1.02          0.0289
                                                                                          \+     664.7500890   17.7    ↑                   1.06          0.0289
                                                                                          \+     702.8673044   17.1    ↑                   1.05          0.0289
                                                                                          \+     760.6118168   18.3    ↑                   1.02          0.0289
                                                                                          −      336.7892724   17.9    ↑                   1.02          0.0350
                                                                                          \+     622.6270105   18.4    ↓                   −1.11         0.0491
                                                                                          \+     724.4910051   20.4    ↓                   −1.04         0.0491

###### 

Metabolites, among the LASSO identified ions, that show statistically significant differences based on menopausal status (pre/post), ER (+/−) and HER2 (+/−).

  M/z        RT         Menopause   ER          Her2
  ---------- ---------- ----------- ----------- -----------
  239.1486   109.0287   0.849       **0.045**   0.437
  179.1841   135.8769   **0.026**   0.432       0.226
  121.2079   338.3861   **0.049**   0.788       **0.000**
  178.0316   136.0036   0.124       0.3         **0.036**
  417.1127   338.331    0.238       0.997       **0.022**
  454.4747   337.7336   0.538       0.388       **0.003**
  622.627    18.4193    **0.04**    0.777       0.280
  724.491    20.4252    0.269       0.407       **0.004**
  788.4464   20.4252    0.649       0.673       **0.001**
  466.729    17.86      **0.026**   0.774       0.133

P-values are in bold when statistically significant at p\<0.05.

###### 

The verified and unverified metabolites.

  M/Z                      RT(sec)   RT(min)   Monoisotopic mass   Putative name of the compound      FC         q-value
  ------------------------ --------- --------- ------------------- ---------------------------------- ---------- ----------
  Verified metabolites                                                                                           
  247.1071                 187       3.12      247.1070665         N-Acetyl-Dtryptophan               −2.02309   0.049087
  134.0966                 136       2.27      134.0965659         1,2,3,4-tetrahydroisoquinoline     −1.12989   0.049087
  179.0568                 136       2.27      179.0567725         Gluconolactone                     −1.26445   0.049087
  513.3184                 351       5.85      513.3184402         Phosphatidyl Glycerol (18:0/0:0)   −1.45152   0.049087
  174.1487                 234       3.90      174.1487168         9-amino-nonanoic acid              −1.15122   0.028858
  433.2574                 440       7.33      433.2574371         Hydrocortisone butyrate            −1.08314   0.028858
  Unverified metabolites                                                                                         
  620.5977                 19        0.32      620.5977263         Ceramide (d18:2/22:0)              −1.08974   0.028858
  429.2271                 365       6.08      429.2270941         Phosphatidyl glycerol (12:0/0:0)   1.03441    0.019619

[^1]: Contributed equally
